Faculty: Stephen J. Kish, PhD

Stephen J. Kish, PhDStephen J. Kish, PhD
Professor, Psychiatry, Pharmacology   
Head, Human Neurochemical Pathology Laboratory
Centre for Addiction and Mental Health

General Area of Research: Human Psychostimulant Abuse, Neuropharmacology/Human Brain Neurochemistry

The focus of our studies is to make use of different imaging modalities (PET and MRI)) to understand the brain mechanisms involved in drug addiction including addiction to psychostimulants such as cocaine and methamphetamine and to cannabis and alcohol. This work primarily involves brain imaging studies in drug addicted populations and in individuals with impulse controls disorders. 

Selected Publications:

Rusjan PM, Wilson AA, Mizrahi R, Boileau I, Chavez SE, Lobaugh NJ, Kish SJ,Houle S, Tong J. Mapping human brain fatty acid amide hydrolase activity with PET. J Cereb Blood Flow Metab. 2012 Dec 5. doi: 10.1038/jcbfm.2012.180. [Epub ahead of print] PubMed PMID: 23211960.

Boileau I, Payer D, Chugani B, Lobo D, Behzadi A, Rusjan PM, Houle S, Wilson AA, Warsh J, Kish SJ, Zack M. The D(2/3) dopamine receptor in pathological gambling: a positron emission tomography study with [(11)C]-(+)-propyl-hexahydro-naphtho-oxazin and [(11) C]raclopride. Addiction. 2012 Nov 20. doi: 10.1111/add.12066. [Epub ahead of print] PubMed PMID: 23167711.

Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, Wilkins D, Selby P, George TP, Zack M, Furukawa Y, McCluskey T, Wilson AA, Kish SJ. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci.2012 Jan 25;32(4):1353-9. doi: 10.1523/JNEUROSCI.4371-11.2012. PubMed PMID: 22279219; PubMed Central PMCID: PMC3532027.

Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, Boileau I, Kish SJ. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry. 2012 Apr;169(4):389-96. doi: 10.1176/appi.ajp.2011.10070937. PubMed PMID: 22193527.

Tong J, Boileau I, Furukawa Y, Chang LJ, Wilson AA, Houle S, Kish SJ. Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab. 2011 Oct;31(10):2065-75. doi: 10.1038/jcbfm.2011.63. Epub 2011 Apr 27. PubMed PMID: 21522164; PubMed Central PMCID: PMC3208151.

Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, Wilkins D, Houle S, Meyer J, Mundo E, Wilson AA, Rusjan PM, Saint-Cyr JA, Guttman M, Collins DL, Shapiro C, Warsh JJ, Boileau I. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.Brain. 2010 Jun;133(Pt 6):1779-97. doi: 10.1093/brain/awq103. Epub 2010 May 17. PubMed PMID: 20483717; PubMed Central PMCID: PMC2912692.

Boileau I, Houle S, Rusjan PM, Furukawa Y, Wilkins D, Tong J, Selby P, Wilson AA, Kish SJ. Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans. Synapse. 2010 Jun;64(6):417-20. doi: 10.1002/syn.20743. PubMed PMID: 20169578.

Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, Hornykiewicz O, Furukawa Y, Wilson AA, Kapur S, Kish SJ. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. Brain. 2009 May;132(Pt 5):1366-75. doi: 10.1093/brain/awn337. Epub 2009 Jan 19. PubMed PMID: 19153147.

Kish SJ, Fitzmaurice PS, Boileau I, Schmunk GA, Ang LC, Furukawa Y, Chang LJ, Wickham DJ, Sherwin A, Tong J. Brain serotonin transporter in human methamphetamine users. Psychopharmacology (Berl). 2009 Mar;202(4):649-61. doi:10.1007/s00213-008-1346-x. Epub 2008 Oct 8. PubMed PMID: 18841348.

Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P, Guttman M, Saint-Cyr JA, Wilson AA, Kish SJ. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci. 2008 Sep 24;28(39):9850-6. doi: 10.1523/JNEUROSCI.3008-08.2008. PubMed PMID: 18815269.

Tong J, Wilson AA, Boileau I, Houle S, Kish SJ. Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse. 2008 Nov;62(11):873-6. doi: 10.1002/syn.20573. PubMed PMID: 18720517.

Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, Houle S, Wilson A, Mundo E, Rusjan P, Meyer J, Kish SJ. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol. 2007 May;14(5):523-8. PubMed PMID: 17437611.

Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, Houle S, Wilson AA, Meyer JH, Kish SJ. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C] DASB. Mov Disord. 2008 Sep 15;23(12):1776-80. doi: 10.1002/mds.22212. PubMed PMID: 18661545.


Stephen J. Kish, Ph.D. 
Head, Human Neurochemical Pathology Laboratory 
Centre for Addiction and Mental Health 
250 College Street 
Toronto, Ontario 
M5T 1R8 
Phone: [416] 535-8501, Ext: 6256 
FAX: [416] 979-6871 
Email: stephen.kish@camh.ca